Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 458, 405-406 (26 March 2009) | doi:10.1038/458405a; Published online 25 March 2009
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Director, Division of Materials Research
- National Science Foundation
- Arlington, VA
Assistant Professor of Medicine
- Massachusetts General Hospital
- Boston, MA
The dangers of diagnostic monopolies
Robert Cook-Deegan1, Subhashini Chandrasekharan1 & Misha Angrist1
- Robert Cook-Deegan, Subhashini Chandrasekharan and Misha Angrist, are at the Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA.
Email: gelp@duke.edu
Abstract
In the first of two commentaries on intellectual property, Robert Cook-Deegan, Subhashini Chandrasekharan and Misha Angrist show how the United States can address glitches with exclusive licences.
Gene patents are meant to encourage innovation, but in DNA diagnostics, they have stirred controversy. Amid worries and worst-case scenarios, there are few empirical studies to help form an accurate picture of how patents affect clinical genetic testing in the United States.
To read this story in full you will need to login or make a payment (see right).
